TRENTON, N.J. - A federal court invalidated the patent on Friday for Merck & Co.'s second-largest selling drug, the blockbuster osteoporosis treatment Fosamax, in a decision that offers millions of patients hope for a cheaper version sooner, but darkens the company's already clouded outlook.... ...
Note: this page has been archived under Muzi Premium Version and is only available to premium members. Please use the Premium Personal Password (PPP) to log in.